Evidence map›Paper›PMID 34374069›Full record

ArticleBritish journal of haematology2021

Urinary retinol binding protein predicts renal outcome in systemic immunoglobulin light-chain (AL) amyloidosis.

Tamer Rezk, Rashim Salota, Jaslyn J Gan, Helen J Lachmann, Marianna Fontana, Keith Siew, Ana Martinez-Naharro, Christianne Guillotte, Paul Bass, Sajitha Sachchithanantham and 11 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 2 countries.

Tamer RezkDivision of Medicine, National Amyloidosis Centre, University College London, London, UK.ORCID 0000-0002-1219-1110
Rashim SalotaEpsom and St Helier's University Hospitals, London, UK.
Jaslyn J GanDivision of Medicine, National Amyloidosis Centre, University College London, London, UK.
Helen J LachmannDivision of Medicine, National Amyloidosis Centre, University College London, London, UK.
Marianna FontanaDivision of Medicine, National Amyloidosis Centre, University College London, London, UK.
Keith SiewDivision of Medicine, UCL Department of Nephrology, University College London, London, UK.
Ana Martinez-NaharroDivision of Medicine, National Amyloidosis Centre, University College London, London, UK.
Christianne GuillotteDivision of Medicine, National Amyloidosis Centre, University College London, London, UK.
Paul BassDivision of Medicine, UCL Department of Nephrology, University College London, London, UK.
Sajitha SachchithananthamDivision of Medicine, National Amyloidosis Centre, University College London, London, UK.
Shameem MahmoodDivision of Medicine, National Amyloidosis Centre, University College London, London, UK.
Aviva PetrieUCL Eastman Dental Institute, London, UK.
Carol J WhelanDivision of Medicine, National Amyloidosis Centre, University College London, London, UK.
Jennifer H PinneyDivision of Medicine, National Amyloidosis Centre, University College London, London, UK.
Mark DockrellEpsom and St Helier's University Hospitals, London, UK.
Darren FoardDivision of Medicine, National Amyloidosis Centre, University College London, London, UK.
Thirusha LaneDivision of Medicine, National Amyloidosis Centre, University College London, London, UK.
Ashutosh D WechalekarDivision of Medicine, National Amyloidosis Centre, University College London, London, UK.
Philip N HawkinsDivision of Medicine, National Amyloidosis Centre, University College London, London, UK.
Stephen B WalshDivision of Medicine, UCL Department of Nephrology, University College London, London, UK.
Julian D GillmoreDivision of Medicine, National Amyloidosis Centre, University College London, London, UK.
Amyloidosis Foundation · USThe London College · GBEpsom and St Helier University Hospitals NHS Trust · GBEastman Dental Hospital · GB

Funding

British Heart Foundation FS/18/21/33447Wellcome TrustWellcome Trust 110182/Z/15/Z
6 · The paper itself

Abstract

Renal risk stratification in systemic immunoglobulin light-chain (AL) amyloidosis is according to estimated glomerular filtration rate (eGFR) and urinary protein creatinine ratio (uPCR), the latter attributed to glomerular dysfunction, with proximal tubular dysfunction (PTD) little studied. Urinary retinol binding protein 4 (uRBP), a low molecular weight tubular protein and highly sensitive marker of PTD, was prospectively measured in 285 newly diagnosed, untreated patients with systemic AL amyloidosis between August 2017 to August 2018. At diagnosis, the uRBP/creatinine ratio (uRBPCR) correlated with serum creatinine (r = 0·618, P < 0·0001), uPCR (r = 0·422, P < 0·0001) as well as both fractional excretion of phosphate and urate (r = 0·563, P < 0·0001). Log uRBPCR at diagnosis was a strong independent predictor of end-stage renal disease {hazard ratio [HR] 2·65, [95% confidence interval (CI) 1·06-6·64]; P = 0·038}, particularly in patients with an eGFR >30 ml/min/1.73 m

Indexed as

AdultAgedAged, 80 and overFemaleHumansImmunoglobulin Light-chain AmyloidosisKidneyKidney DiseasesMaleMiddle AgedRetinol-Binding Proteins, PlasmaRisk FactorsSurvival AnalysisRBP4 protein, humanRetinol-Binding Proteins, Plasmaamyloidchemotherapymyelomarenal medicine

Identifiers

PMID34374069
PMCPMC12086741
OpenAlexW3188409975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.